This study analyzed the long-term effect of behavioral counseling on increasing daily physical activity (PA) and reducing sedentary (SED) time on changes in beta-cell (β-cell) function and glucose control in patients with type 2 diabetes (T2D). The authors concluded that increasing moderate-to-vigorous-intensity physical activity (MVPA) and reducing SED time can effectively preserve the β-cell function of the pancreas and improve glucose control in these patients.

This review assessed the effect of vitamin B12 supplementation on clinical outcomes when used alone or combined with other treatments for diabetic peripheral neuropathy (PN). The authors concluded that a greater reduction of PN symptoms occurred with the use of B12 supplementation alone or in combination with other treatments compared to placebo.

This study investigated the safety and effectiveness of intermittent fasting (IF) for 3 non-consecutive days a week, over a period of 12 weeks in people with insulin-treated type 2 diabetes (T2D). The authors concluded that this dietary approach was safe and effective for controlling blood glucose, reducing total daily insulin requirements, and decreasing body weight in participants with T2D.

This study evaluated evidence on the association between physical activity and major diabetes-related complications in patients with diabetes. The authors concluded that physical activity was associated with a reduction in the occurrence of major diabetes-related complications, even if performed at levels lower than recommended.

This study looked at the use of metformin (Glucophage) for the management of type 2 diabetes (T2D) in pregnancy. The study showed that compared to infants exposed to placebo, those exposed to metformin during pregnancy did not show any signs of increased weight or body mass index (BMI; a measurement of weight in relation to height) after two years.

This study compared intermittent scanning continuous glucose monitoring (isCGM) with real-time continuous glucose monitoring (rtCGM) for the treatment of type 1 diabetes (T1D). It found that compared to isCGM, rt CGM resulted in increased time spent in range and improved blood glucose control in these patients. 

This study analyzed the safety and effectiveness of dapagliflozin (Farxiga) in patients with type 2 diabetes (T2D) across different ranges of baseline systolic blood pressure (SBP; blood pressure when the heart beats). The data suggested that dapagliflozin reduced the risk of hospitalization for heart failure (HHF) and kidney-related outcomes and was safe for use across different levels of SBP without causing an increase in short-term (acute) kidney injury, dehydration, or amputations in patients.

This study evaluated the effectiveness of panretinal photocoagulation (PRP) plus intravitreal anti-VEGF treatment versus PRP alone for the treatment of patients with diabetic retinopathy (DR; diabetic eye disease). The data showed that PRP with anti-VEGF combination treatment improved vision without an increase in side effects compared to PRP alone in these patients.

This study evaluated the long-term effects of a moderate low-carbohydrate diet (LCD) on blood glucose control and liver function in patients with type 2 diabetes (T2D). The data showed that patients on a moderate LCD diet showed better blood glucose control and liver function over the long term than patients on a traditional diabetic diet (TDD).

This study evaluated the effectiveness, durability, and safety of faricimab (Vabysmo) for the treatment of patients with diabetic macular edema (DME). The data showed that faricimab with extended dosing up to every 16 weeks was safe and showed good vision gains and clinical improvements in these patients.